Skip to main content
. Author manuscript; available in PMC: 2020 Sep 29.
Published in final edited form as: Gynecol Oncol. 2019 Mar;152(3):445–451. doi: 10.1016/j.ygyno.2018.11.028

Figure 1. Timeline of publication and FDA approval of available maintenance regimens in platinum-sensitive recurrent ovarian cancer.

Figure 1.

-gBRCA=germline BRCA mutation cohort; tBRCA=germline- and somatic-BRCA mutation cohort; HRD=homologous recombination deficiency; wBRCA=wild-type BRCA

-PFS times are in bold and compare novel therapy versus control